Healthcare

Ansell (ASX:ANN) has reported its FY26 financial results, highlighting stronger margins, improved earnings delivery and continued progress in strengthening its balance sheet.

Immuron (ASX:IMC) has continued strengthening its commercial foundation through growth in its flagship Travelan product while progressing a pipeline of biotechnology opportunities across infectious disease and immune-based therapies.

Cyclopharm (ASX:CYC) is entering a new phase of commercial expansion after delivering record first-half results and accelerating adoption of its Technegas lung imaging technology across the United States.

ParagonCare (ASX:PGC) has continued to build its position as a diversified healthcare distributor across the Asia Pacific region, supported by its integrated operating platform covering healthcare products, medical technology, consumables, pharmaceuticals, logistics and manufacturing. The company’s FY26 financial results highlighted continued revenue growth and …

Micro-X (ASX:MX1) is continuing to develop its position in the medical technology sector through its lightweight X-ray imaging platforms and emerging healthcare applications. The Adelaide-based company is focused on commercialising its carbon nanotube-enabled technology across mobile medical imaging, stroke diagnostics and security screening markets.

Argenica Therapeutics (ASX:AGN) continues progressing development of its lead neuroprotective peptide Xaranetide, with recent safety milestones and additional research supporting the company’s next clinical steps.

EBR Systems (ASX:EBR) continues advancing the commercial rollout of its WiSE CRT System, with implant volumes, hospital adoption and reimbursement progress becoming central themes for the medical technology company.